IBDEI031 ; ; 18-NOV-2013
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;NOV 18, 2013
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,3565,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3565,1,4,0)
 ;;=4^281.0
 ;;^UTILITY(U,$J,358.3,3565,1,5,0)
 ;;=5^Vit B12 Deficiency (Pernicious Anemia)
 ;;^UTILITY(U,$J,358.3,3565,2)
 ;;=^7161
 ;;^UTILITY(U,$J,358.3,3566,0)
 ;;=282.60^^31^223^101
 ;;^UTILITY(U,$J,358.3,3566,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3566,1,4,0)
 ;;=4^282.60
 ;;^UTILITY(U,$J,358.3,3566,1,5,0)
 ;;=5^Sickle-Cell Anemia
 ;;^UTILITY(U,$J,358.3,3566,2)
 ;;=^7188
 ;;^UTILITY(U,$J,358.3,3567,0)
 ;;=282.62^^31^223^102
 ;;^UTILITY(U,$J,358.3,3567,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3567,1,4,0)
 ;;=4^282.62
 ;;^UTILITY(U,$J,358.3,3567,1,5,0)
 ;;=5^Sickle-Cell With Crisis
 ;;^UTILITY(U,$J,358.3,3567,2)
 ;;=^267982
 ;;^UTILITY(U,$J,358.3,3568,0)
 ;;=281.1^^31^223^112
 ;;^UTILITY(U,$J,358.3,3568,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3568,1,4,0)
 ;;=4^281.1
 ;;^UTILITY(U,$J,358.3,3568,1,5,0)
 ;;=5^Vit B12 Deficiency(Dietary)
 ;;^UTILITY(U,$J,358.3,3568,2)
 ;;=^267974
 ;;^UTILITY(U,$J,358.3,3569,0)
 ;;=286.7^^31^223^45
 ;;^UTILITY(U,$J,358.3,3569,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3569,1,4,0)
 ;;=4^286.7
 ;;^UTILITY(U,$J,358.3,3569,1,5,0)
 ;;=5^Coagulation Defect(Any),Acquired
 ;;^UTILITY(U,$J,358.3,3569,2)
 ;;=^2235
 ;;^UTILITY(U,$J,358.3,3570,0)
 ;;=289.9^^31^223^108
 ;;^UTILITY(U,$J,358.3,3570,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3570,1,4,0)
 ;;=4^289.9
 ;;^UTILITY(U,$J,358.3,3570,1,5,0)
 ;;=5^Thrombocytosis, Essential
 ;;^UTILITY(U,$J,358.3,3570,2)
 ;;=^55344
 ;;^UTILITY(U,$J,358.3,3571,0)
 ;;=451.9^^31^223^109
 ;;^UTILITY(U,$J,358.3,3571,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3571,1,4,0)
 ;;=4^451.9
 ;;^UTILITY(U,$J,358.3,3571,1,5,0)
 ;;=5^Thrombophlebitis 
 ;;^UTILITY(U,$J,358.3,3571,2)
 ;;=^93357
 ;;^UTILITY(U,$J,358.3,3572,0)
 ;;=446.6^^31^223^110
 ;;^UTILITY(U,$J,358.3,3572,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3572,1,4,0)
 ;;=4^446.6
 ;;^UTILITY(U,$J,358.3,3572,1,5,0)
 ;;=5^Thrombotic Thrombocytopenic Purpura(Ttp)
 ;;^UTILITY(U,$J,358.3,3572,2)
 ;;=^119061
 ;;^UTILITY(U,$J,358.3,3573,0)
 ;;=286.4^^31^223^113
 ;;^UTILITY(U,$J,358.3,3573,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3573,1,4,0)
 ;;=4^286.4
 ;;^UTILITY(U,$J,358.3,3573,1,5,0)
 ;;=5^Von Willebrand'S Disease
 ;;^UTILITY(U,$J,358.3,3573,2)
 ;;=^127267
 ;;^UTILITY(U,$J,358.3,3574,0)
 ;;=204.00^^31^223^5
 ;;^UTILITY(U,$J,358.3,3574,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3574,1,4,0)
 ;;=4^204.00
 ;;^UTILITY(U,$J,358.3,3574,1,5,0)
 ;;=5^All, W/O Remission
 ;;^UTILITY(U,$J,358.3,3574,2)
 ;;=^267521
 ;;^UTILITY(U,$J,358.3,3575,0)
 ;;=204.01^^31^223^4
 ;;^UTILITY(U,$J,358.3,3575,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3575,1,4,0)
 ;;=4^204.01
 ;;^UTILITY(U,$J,358.3,3575,1,5,0)
 ;;=5^All, In Remission
 ;;^UTILITY(U,$J,358.3,3575,2)
 ;;=^267522
 ;;^UTILITY(U,$J,358.3,3576,0)
 ;;=204.10^^31^223^42
 ;;^UTILITY(U,$J,358.3,3576,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3576,1,4,0)
 ;;=4^204.10
 ;;^UTILITY(U,$J,358.3,3576,1,5,0)
 ;;=5^Cll, W/O Remission
 ;;^UTILITY(U,$J,358.3,3576,2)
 ;;=^267523
 ;;^UTILITY(U,$J,358.3,3577,0)
 ;;=204.11^^31^223^41
 ;;^UTILITY(U,$J,358.3,3577,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3577,1,4,0)
 ;;=4^204.11
 ;;^UTILITY(U,$J,358.3,3577,1,5,0)
 ;;=5^Cll, In Remission
 ;;^UTILITY(U,$J,358.3,3577,2)
 ;;=^267524
 ;;^UTILITY(U,$J,358.3,3578,0)
 ;;=201.90^^31^223^72
 ;;^UTILITY(U,$J,358.3,3578,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3578,1,4,0)
 ;;=4^201.90
 ;;^UTILITY(U,$J,358.3,3578,1,5,0)
 ;;=5^Hodgkin'S Lymphoma, Unpsec Type & Site
 ;;^UTILITY(U,$J,358.3,3578,2)
 ;;=^267430
 ;;^UTILITY(U,$J,358.3,3579,0)
 ;;=785.6^^31^223^79
 ;;^UTILITY(U,$J,358.3,3579,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3579,1,4,0)
 ;;=4^785.6
 ;;^UTILITY(U,$J,358.3,3579,1,5,0)
 ;;=5^Lymphadenopathy
 ;;^UTILITY(U,$J,358.3,3579,2)
 ;;=^72368
 ;;^UTILITY(U,$J,358.3,3580,0)
 ;;=200.20^^31^223^80
 ;;^UTILITY(U,$J,358.3,3580,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3580,1,4,0)
 ;;=4^200.20
 ;;^UTILITY(U,$J,358.3,3580,1,5,0)
 ;;=5^Lymphoma, Burkitt'S, Unspecified Sites
 ;;^UTILITY(U,$J,358.3,3580,2)
 ;;=^17529
 ;;^UTILITY(U,$J,358.3,3581,0)
 ;;=202.00^^31^223^82
 ;;^UTILITY(U,$J,358.3,3581,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3581,1,4,0)
 ;;=4^202.00
 ;;^UTILITY(U,$J,358.3,3581,1,5,0)
 ;;=5^Lymphoma, Low-Grade, Unspec Site
 ;;^UTILITY(U,$J,358.3,3581,2)
 ;;=^72606
 ;;^UTILITY(U,$J,358.3,3582,0)
 ;;=200.10^^31^223^81
 ;;^UTILITY(U,$J,358.3,3582,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3582,1,4,0)
 ;;=4^200.10
 ;;^UTILITY(U,$J,358.3,3582,1,5,0)
 ;;=5^Lymphoma, Int Or High Grade, Unspec Site
 ;;^UTILITY(U,$J,358.3,3582,2)
 ;;=^175886
 ;;^UTILITY(U,$J,358.3,3583,0)
 ;;=273.3^^31^223^83
 ;;^UTILITY(U,$J,358.3,3583,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3583,1,4,0)
 ;;=4^273.3
 ;;^UTILITY(U,$J,358.3,3583,1,5,0)
 ;;=5^Macroglobulinemia
 ;;^UTILITY(U,$J,358.3,3583,2)
 ;;=^73013
 ;;^UTILITY(U,$J,358.3,3584,0)
 ;;=203.00^^31^223^92
 ;;^UTILITY(U,$J,358.3,3584,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3584,1,4,0)
 ;;=4^203.00
 ;;^UTILITY(U,$J,358.3,3584,1,5,0)
 ;;=5^Multiple Myeloma W/O Rem
 ;;^UTILITY(U,$J,358.3,3584,2)
 ;;=^267514
 ;;^UTILITY(U,$J,358.3,3585,0)
 ;;=203.01^^31^223^91
 ;;^UTILITY(U,$J,358.3,3585,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3585,1,4,0)
 ;;=4^203.01
 ;;^UTILITY(U,$J,358.3,3585,1,5,0)
 ;;=5^Multiple Myeloma In Remission
 ;;^UTILITY(U,$J,358.3,3585,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,3586,0)
 ;;=238.6^^31^223^95
 ;;^UTILITY(U,$J,358.3,3586,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3586,1,4,0)
 ;;=4^238.6
 ;;^UTILITY(U,$J,358.3,3586,1,5,0)
 ;;=5^Plasmacytoma Nos
 ;;^UTILITY(U,$J,358.3,3586,2)
 ;;=^81973
 ;;^UTILITY(U,$J,358.3,3587,0)
 ;;=205.00^^31^223^7
 ;;^UTILITY(U,$J,358.3,3587,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3587,1,4,0)
 ;;=4^205.00
 ;;^UTILITY(U,$J,358.3,3587,1,5,0)
 ;;=5^Aml, W/O Remission
 ;;^UTILITY(U,$J,358.3,3587,2)
 ;;=^267531
 ;;^UTILITY(U,$J,358.3,3588,0)
 ;;=205.01^^31^223^6
 ;;^UTILITY(U,$J,358.3,3588,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3588,1,4,0)
 ;;=4^205.01
 ;;^UTILITY(U,$J,358.3,3588,1,5,0)
 ;;=5^Aml, In Remission
 ;;^UTILITY(U,$J,358.3,3588,2)
 ;;=^267532
 ;;^UTILITY(U,$J,358.3,3589,0)
 ;;=205.10^^31^223^44
 ;;^UTILITY(U,$J,358.3,3589,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3589,1,4,0)
 ;;=4^205.10
 ;;^UTILITY(U,$J,358.3,3589,1,5,0)
 ;;=5^Cml, W/O Remission
 ;;^UTILITY(U,$J,358.3,3589,2)
 ;;=^267533
 ;;^UTILITY(U,$J,358.3,3590,0)
 ;;=205.11^^31^223^43
 ;;^UTILITY(U,$J,358.3,3590,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3590,1,4,0)
 ;;=4^205.11
 ;;^UTILITY(U,$J,358.3,3590,1,5,0)
 ;;=5^Cml, In Remission
 ;;^UTILITY(U,$J,358.3,3590,2)
 ;;=^267534
 ;;^UTILITY(U,$J,358.3,3591,0)
 ;;=289.0^^31^223^46
 ;;^UTILITY(U,$J,358.3,3591,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3591,1,4,0)
 ;;=4^289.0
 ;;^UTILITY(U,$J,358.3,3591,1,5,0)
 ;;=5^Erthryocytosis, Secondary
 ;;^UTILITY(U,$J,358.3,3591,2)
 ;;=^186856
 ;;^UTILITY(U,$J,358.3,3592,0)
 ;;=238.4^^31^223^96
 ;;^UTILITY(U,$J,358.3,3592,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3592,1,4,0)
 ;;=4^238.4
 ;;^UTILITY(U,$J,358.3,3592,1,5,0)
 ;;=5^Polycytheria Rubra Vera
 ;;^UTILITY(U,$J,358.3,3592,2)
 ;;=^96105
 ;;^UTILITY(U,$J,358.3,3593,0)
 ;;=V58.61^^31^223^114
 ;;^UTILITY(U,$J,358.3,3593,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3593,1,4,0)
 ;;=4^V58.61
 ;;^UTILITY(U,$J,358.3,3593,1,5,0)
 ;;=5^Warfarin/Coumadin Use
 ;;^UTILITY(U,$J,358.3,3593,2)
 ;;=Warfarin/Coumadin Use^303459
 ;;^UTILITY(U,$J,358.3,3594,0)
 ;;=282.49^^31^223^106
 ;;^UTILITY(U,$J,358.3,3594,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3594,1,4,0)
 ;;=4^282.49
 ;;^UTILITY(U,$J,358.3,3594,1,5,0)
 ;;=5^Thalassemia Nec
 ;;^UTILITY(U,$J,358.3,3594,2)
 ;;=^329910
 ;;^UTILITY(U,$J,358.3,3595,0)
 ;;=289.89^^31^223^14
 ;;^UTILITY(U,$J,358.3,3595,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3595,1,4,0)
 ;;=4^289.89
 ;;^UTILITY(U,$J,358.3,3595,1,5,0)
 ;;=5^Blood Diseases Nec
 ;;^UTILITY(U,$J,358.3,3595,2)
 ;;=^329887
 ;;^UTILITY(U,$J,358.3,3596,0)
 ;;=238.79^^31^223^77
 ;;^UTILITY(U,$J,358.3,3596,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3596,1,4,0)
 ;;=4^238.79
 ;;^UTILITY(U,$J,358.3,3596,1,5,0)
 ;;=5^LYMPH/HEMATPOITC TIS NEC
 ;;^UTILITY(U,$J,358.3,3596,2)
 ;;=^334033
 ;;^UTILITY(U,$J,358.3,3597,0)
 ;;=287.30^^31^223^97
 ;;^UTILITY(U,$J,358.3,3597,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3597,1,4,0)
 ;;=4^287.30
 ;;^UTILITY(U,$J,358.3,3597,1,5,0)
 ;;=5^Primary Thrombocytopenia
 ;;^UTILITY(U,$J,358.3,3597,2)
 ;;=^332841
 ;;^UTILITY(U,$J,358.3,3598,0)
 ;;=288.09^^31^223^3
 ;;^UTILITY(U,$J,358.3,3598,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3598,1,4,0)
 ;;=4^288.09
 ;;^UTILITY(U,$J,358.3,3598,1,5,0)
 ;;=5^Agranulocytosis
 ;;^UTILITY(U,$J,358.3,3598,2)
 ;;=^334042
 ;;^UTILITY(U,$J,358.3,3599,0)
 ;;=V10.21^^31^223^52
 ;;^UTILITY(U,$J,358.3,3599,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3599,1,4,0)
 ;;=4^V10.21
 ;;^UTILITY(U,$J,358.3,3599,1,5,0)
 ;;=5^H/O Laryngeal Cancer
 ;;^UTILITY(U,$J,358.3,3599,2)
 ;;=^295214
 ;;^UTILITY(U,$J,358.3,3600,0)
 ;;=284.2^^31^223^93
 ;;^UTILITY(U,$J,358.3,3600,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3600,1,4,0)
 ;;=4^284.2
 ;;^UTILITY(U,$J,358.3,3600,1,5,0)
 ;;=5^Myelophthisic Anemia
 ;;^UTILITY(U,$J,358.3,3600,2)
 ;;=^334037
 ;;^UTILITY(U,$J,358.3,3601,0)
 ;;=202.40^^31^223^65
 ;;^UTILITY(U,$J,358.3,3601,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3601,1,4,0)
 ;;=4^202.40
 ;;^UTILITY(U,$J,358.3,3601,1,5,0)
 ;;=5^Hairy Cell Leukemia,Unspecified site
 ;;^UTILITY(U,$J,358.3,3601,2)
 ;;=^69587
 ;;^UTILITY(U,$J,358.3,3602,0)
 ;;=287.49^^31^223^107
 ;;^UTILITY(U,$J,358.3,3602,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3602,1,4,0)
 ;;=4^287.49
 ;;^UTILITY(U,$J,358.3,3602,1,5,0)
 ;;=5^Thrombocytopenia,Drug Induced
 ;;^UTILITY(U,$J,358.3,3602,2)
 ;;=^339610
